Centers of Excellence
Advanced Prostate Cancer
From the Editor
From the Desk of the Editor
Goal: To serve as an interface between community urologists, medical oncologists, radiation oncologists, advanced practice providers, and specialty nurses to remain updated on best practices, areas of controversy, and the latest advances in the care of advanced prostate cancer patients.
Alicia Morgans, MD, MPH
Alicia Morgans, MD, MPH is the Assistant Professor of medicine in the Division of Hematology/Oncology at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. She specializes in the treatment of genitourinary malignancies, including cancers of the prostate, bladder and testis (germ cell) and penis. Dr. Morgans’ research focus is on complications of prostate cancer survivorship and treatment decision making in advanced prostate cancer.
EAU 2016 - Prostate Cancer
- Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
- The PRONOUNCE Trial for patients with advanced prostate cancer and cardiovascular disease receiving degarelix or leuprolide.
- Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry.
- Cardiovascular status and events in patients with prostate cancer treated with a luteinising hormone-releasing hormone agonist or degarelix: A comparison of USA/Canada vs Europe